|
|
|
11-50 employees
View all
|
|
pharmaceuticals
|
|
160 2nd St,Cambridge,Massachusetts,US
|
|
As of January 22, 2013, Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals.Molecular Insight Pharmaceuticals, Inc. develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy.
|
Molecular Insight Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used Molecular Insight Pharmaceuticals email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Molecular Insight Pharmaceuticals customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.